The facts are sourced from an 8-K filing with the SEC via EDGAR, published May 21, 2025. The deal's status is pending regulatory, indicating it had not yet closed as of that filing.
Two financial advisors are disclosed, one per side, both designated lead. Guggenheim Securities, LLC served as financial advisor to ACELYRIN (the target), with the source sentence also noting that Fenwick & West LLP and Paul Hastings LLP served as ACELYRIN's legal counsel. On the acquirer side, Morgan Stanley & Co. LLC served as financial advisor to Alumis, with Cooley LLP serving as Alumis's legal counsel, per the corresponding source sentence.
Legal advisors are disclosed for both sides. Cooley LLP served as legal counsel to the acquirer, Alumis. On the target side, both Paul Hastings LLP and Fenwick & West LLP served as legal counsel to ACELYRIN, reflecting that the target retained two separate law firms for the transaction.
Beyond classifying the transaction as an all-stock merger, the facts block does not specify the exchange ratio, pro forma ownership split, or any other structural terms of the stock consideration.
Several facts are not disclosed in this record. The transaction's dollar value is not stated. No expected closing date is given, and the facts block does not clarify the respective roles of ACELYRIN's two legal advisors, Fenwick & West LLP and Paul Hastings LLP, relative to one another.